Intravenous Metoprolol Versus Intravenous Amiodarone in the Prevention of Atrial Fibrillation After Cardiac Surgery

The aim of the study is to test the efficiency of intravenous administration of metoprolol versus intravenous administration of amiodarone in the prevention of atrial fibrillation after cardiac surgery.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Atrial Fibrillation Arrhythmias, Cardiac Cardiac Surgery Cardiovascular Diseases Heart Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Halonen jari

Kuopio, FIN- 70211, Finland

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

elective CABG and aortic valve patients in cardiac surgery,
previous use of betablocker therapy

Exclusion criteria

previous atrial fibrillation or flutter,
thyroid disease,
uncontrolled heart failure,
II or III degree atrioventricular block

Treatment and study plan

metoprolol, amiodarone

Drug

to compare the effectiviness of intravenous administration of metoprolol and amiodarone in the prevention of atrial fibrillation after cardiac surgery

Primary outcomes

Incidence of atrial fibrillation

Time frame: 48 hours

Sponsors and collaborators

Lead sponsor

Kuopio University Hospital

Other

Collaborators

Tampere University Hospital
Vaasa Central Hospital, Vaasa, Finland

Registry information

Important dates

Study start: 2007
Primary completion: 2009
Study completion: 2009
First posted: Nov 3, 2008
Registry last updated: Nov 24, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed